Alabama Pharmacist Defense Attorney

Alabama Pharmacist Defense Attorney KREPS LAW FIRM, LLC – (866) 348-2889. Alabama Pharmacist Defense Attorney – Investigation? Cha Call us to learn more - (866) 348-2889.

No matter what others may say, do not go through the process alone if you have been charged by the Alabama State Board of Pharmacy or are being investigated. We want to talk to you and get to know you and your story so we can help you through this difficult situation. Right now you feel like everyone is out to get you - your employer, the complainant, your superiors, etc. We can help you see the b

ig picture and guide you and give you hope. We regularly handle professional board matters before the Alabama State Board of Pharmacy. Our practice involves helping professionals deal with board issues ranging from alleged drug diversion, addiction issues, patient safety issues, and all other aspects of the regulation of the Pharmacy Profession in Alabama. We are members of the Federation of Associations of Regulatory Boards and have attended the attorney certification program CLE. These are the general steps that we recommend you take if you are under investigation or have been questioned at your job. These are general recommendations and are not legal advice and we urge you to consult with an attorney in our office.

1. If you have been terminated from employment, you should request a copy of your complete personnel file immediately.

2. If you have been accused of using or diverting controlled medication, you need to contact us immediately for further information.

3. If you have received a letter of investigation from the board or you have been contacted by an investigator, our advice to you is consult with an attorney prior to making any statements or making any decisions about the temporary status of your license.

4. Prior to meeting with the board or the board’s investigator, you should retain counsel to enter an appearance on your behalf and advise you through the process.

5. You do not need to talk about your case with anyone other than those people authorized by your attorney. Many times evidence that you provide will be used against you throughout the process.

6. Although the administrative process as it relates to a professional license is different than the criminal process, you definitely need an attorney to advise you and to negotiate for you and to speak on your behalf. Many times things are said and done by a professional without counsel that can be extremely detrimental to your cause and can result in much more serious consequences as it relates to your license. Arguments and aspects can be explored that you may not be aware of whenever you are looking at your case alone.

7. Do not discuss your case with co-workers, former co-workers, pharmacist friends, pharmacists previously disciplined by the Board, etc. This will not help and will likely make you more anxious and worried and will confuse you. Every Board matter is different and the facts of each case are different. Call us immediately if you have been contacted by the Alabama Board of Pharmacy regarding your professional license and we will be glad to speak with you and go through the process with you. (866) 348-2889

“No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers.”

       September 03, 2025Women Face 45% Higher Mortality Risk From Beta-Blockers After Heart AttackWomen treated with be...
09/05/2025



September 03, 2025

Women Face 45% Higher Mortality Risk From Beta-Blockers After Heart Attack

Women treated with beta-blockers (β-blockers) for post-myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF) have a 45% increased risk of MI, heart failure hospitalization, or death compared with men, according to new study findings.

www.KrepsLawFirm.com/alabama-board-of-pharmacy-defense-lawyer

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

       August 12, 2025Brensocatib Becomes First Approved Treatment for Non-Cystic Fibrosis Bronchiectasis in Adults, Ado...
08/14/2025



August 12, 2025

Brensocatib Becomes First Approved Treatment for Non-Cystic Fibrosis Bronchiectasis in Adults, Adolescents

Brensocatib (Brinsupri; Insmed Incorporated) received FDA approval as a treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older, supported by data from the phase 3 ASPEN (NCT04594369) and phase 2 WILLOW studies (NCT03218917).

www.KrepsLawFirm.com/alabama-board-of-pharmacy-defense-lawyer

Brensocatib emerges as the first FDA-approved treatment for non-cystic fibrosis bronchiectasis, revolutionizing care and targeting chronic inflammation.

         August 01, 2025Inclisiran Receives FDA Approval for New Indication to Treat HypercholesterolemiaThe FDA has app...
08/04/2025



August 01, 2025

Inclisiran Receives FDA Approval for New Indication to Treat Hypercholesterolemia

The FDA has approved a label update for inclisiran (Leqvio; Novartis Pharmaceuticals), allowing its use as monotherapy, in addition to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia.1

www.KrepsLawFirm.com/alabama-pharmacist-defense-attorney

FDA approves inclisiran as a monotherapy to effectively lower low-density lipoprotein cholesterol in adults with hypercholesterolemia, enhancing heart disease prevention strategies.

         August 01, 2025Vizz Becomes First, Only FDA-Approved Aceclidine-Based Eye Drop for PresbyopiaThe FDA approved a...
08/03/2025



August 01, 2025

Vizz Becomes First, Only FDA-Approved Aceclidine-Based Eye Drop for Presbyopia

The FDA approved aceclidine ophthalmic solution 1.44% (Vizz; Lenz Therapeutics) for the treatment of presbyopia in adult patients.

www.KrepsLawFirm.com/alabama-board-of-pharmacy-defense-lawyer

The FDA approves aceclidine ophthalmic solution 1.44%, the first aceclidine eye drop for presbyopia, offering a new solution for millions struggling with near vision loss.

       July 31, 2025Women With Hypoglycemia Prior to Pregnancy Are More Likely to Have Adverse OutcomesIn an analysis pu...
08/02/2025



July 31, 2025

Women With Hypoglycemia Prior to Pregnancy Are More Likely to Have Adverse Outcomes

In an analysis published in PLoS, investigators found that women who are Chinese with low blood sugar levels prior to pregnancy were more likely to have adverse pregnancy outcomes.

www.KrepsLawFirm.com/alabama-board-of-pharmacy-defense-lawyer

Study reveals that women with low preconception blood sugar face higher risks of adverse pregnancy outcomes, emphasizing the need for screening and education.

         July 28, 2025FDA Approves Sepiapterin for Adults, Children Living With PhenylketonuriaThe FDA has granted regul...
07/31/2025



July 28, 2025

FDA Approves Sepiapterin for Adults, Children Living With Phenylketonuria

The FDA has granted regulatory approval to sepiapterin (Sephience; PTC Therapeutics) for the treatment of adults and children living with phenylketonuria (PKU), a rare, inherited metabolic disease that impacts the brain and leads to a buildup of the amino acid phenylalanine (Phe), according to a news release from PTC Therapeutics.1,2

www.KrepsLawFirm.com/alabama-pharmacist-defense-attorney

Sepiapterin treatment allowed for patients to liberalize their diet while reaching or exceeding recommended daily protein allowances in patients living with phenylketonuria.

         July 07, 2025FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary ImmunodeficiencyThe FDA h...
07/09/2025



July 07, 2025

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

The FDA has announced the approval of Gammagard Liquid ERC (enhanced removal capability; immune globulin infusion [human]), a formulation of immunoglobulin that can be administered subcutaneously or intravenously and contains less than or equal to 2 µg/mL of immunoglobulin A (IgA) in a 10% solution, as replacement therapy for the treatment of patients aged 2 years and older with primary immunodeficiency (PI), according to a news release from Takeda Pharmaceuticals.1

www.KrepsLawFirm.com/alabama-pharmacist-defense-attorney

The new formulation contains little immunoglobulin A, reducing possible risks associated with infusion in patients with primary immunodeficiency.

         July 04, 2025Hospitalized Adults With Community-Acquired Pneumonia Suffer Significant Morbidity PostdischargeAd...
07/07/2025



July 04, 2025

Hospitalized Adults With Community-Acquired Pneumonia Suffer Significant Morbidity Postdischarge

Adults hospitalized for community-acquired pneumonia are at high risk of losing the ability to perform basic and instrumental activities of daily living (ADLs), losing their employment status, and suffering from poor quality of life (QoL) at 6 months postdischarge compared with their pre-illness statuses, according to the results of a prospective cohort study published in BMC Infectious Diseases.1

www.KrepsLawFirm.com/alabama-board-of-pharmacy-defense-lawyer

Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability to perform activities and experiencing poor quality of life.

           July 04, 2025Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Swit...
07/06/2025



July 04, 2025

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Patients with inflammatory conditions achieved similar clinical outcomes after switching from the reference adalimumab (Humira; AbbVie) to a biosimilar, according to real-world data presented at the 2025 American Society of Health-System Pharmacists Pharmacy Futures Meeting.

www.KrepsLawFirm.com/alabama-pharmacist-defense-attorney

Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.

Address

1932 Laurel Road
Birmingham, AL
35216

Alerts

Be the first to know and let us send you an email when Alabama Pharmacist Defense Attorney posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Alabama Pharmacist Defense Attorney:

Share